Sound Bioventures

Sound Bioventures expands portfolio with new investment in US company NephroDI Therapeutics to accelerate development of NDI-5001 for pediatric orphan kidney disease

New funding will accelerate NephroDI’s asset, NDI-5001, into and through clinical proof of concept in Congenital Nephrogenic Diabetes Insipidus (NDI) New investment complements NephroDI’s previously announced strategic corporate partnership NDI-5001 has the potential to become a first-in-class therapy for X-linked NDI 20 June 2024, Stockholm, Sweden and Washington D.C., US - Sound Bioventures, a venture...
Epic Spaces, Nordenskiöldsgatan 11A, 211 19 Malmö, Sweden